All In Biotech

Drug Trial Radar · NCT06906367

A Study of Patients With Fabry Disease (US Specific)

A Prospective, Observational Study of Patients With Fabry Disease (US Specific)

Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

450

Planned (sponsor's estimate)

Start

Feb 13, 2026

Primary completion

Jun 2032

Study completion Jun 2032

Sponsor

Lead sponsor
Amicus TherapeuticsIndustry
Sponsor type
Industry
First posted
Apr 2, 2025

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an observational study to evaluate the effects of treatment on long-term effectiveness, safety, and health-related quality of life (HRQOL) in patients with Fabry disease, with a main focus on migalastat.

Conditions

  • Fabry Disease

Interventions

  • migalastat HClDrug

    Non-interventional study of participants receiving migalastat HCl 150 mg

  • ERTDrug

    Non-interventional study of participants receiving enzyme replacement therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized rate of change in Estimated Glomerular Filtration Rate (eGFR)Time frame: Baseline and prospective up to 5 years

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • UAB Nephrology Research Clinic at Paula Building

    Birmingham, Alabama · Recruiting

  • Arkansas Children's Hospital

    Little Rock, Arkansas · Recruiting

  • Emory Genetics

    Atlanta, Georgia · Recruiting

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

  • New York-Presbyterian Morgan Stanley Children's Hospital - Columbia University Medical Center

    New York, New York · Not yet recruiting

  • UPMC Children's Hospital of Pittsburgh

    Pittsburgh, Pennsylvania · Recruiting

  • Renal Disease Research Institute

    Dallas, Texas · Recruiting

  • Lysosomal and Rare Disorders Research and Treatment Center, Inc.

    Fairfax, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.